Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral Formulations.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or primary data synthesis
PubMed 36694887 · doi:10.17925/EE.2022.18.2.133
What was done
This was a narrative review summarizing testosterone replacement therapy options for male hypogonadism. The paper specifically examined the pharmacokinetics, delivery mechanism (self-emulsifying drug delivery systems and lymphatic absorption), and safety profiles of newly FDA-approved oral testosterone undecanoate formulations (JATENZO and TLANDO) alongside conventional transdermal and injectable options.
What was found
The abstract reports that male hypogonadism affects 10–30% of the male population. It notes that the oral testosterone undecanoate formulations JATENZO and TLANDO overcome delivery limitations via lymphatic absorption without evidence of liver dysfunction. No primary trial numerical efficacy or safety outcomes are reported in the abstract.
Why it matters
It highlights newly approved oral testosterone options that circumvent traditional oral bioavailability limitations and hepatic adverse effects, expanding delivery modalities for hypogonadal men.
Limits
This is a narrative review with no systematic search criteria, quality appraisal, or meta-analytic synthesis. The abstract includes no primary data, participant counts, comparative effect estimates, or long-term safety figures.
Cited by
- supports Oral formulations Tlando, Jatenzo, and Kyzatrex deliver testosterone undecanoate via lymphatic absorption without requiring 17-alpha-alkylation, avoiding the classic first-pass hepatotoxicity of older oral androgens.